A New Turning Point in Obesity Treatment, EPPE!

Recently, the name of the obesity treatment developed by Hanmi Pharmaceutical has been finalized as EPPE. This name was derived from the first part of the international nonproprietary name, efpeglenatide, and was thoughtfully chosen for easy public recall. As obesity is becoming an increasingly serious issue in modern society, the launch of such an innovative treatment is generating significant anticipation.

Features of Efpeglenatide

Efpeglenatide is a GLP-1 receptor agonist, utilizing the long-acting platform technology Lapscovery, which allows for once-weekly administration. This drug is characterized by its slow absorption and stable blood concentration maintenance, offering patients a more effective approach to obesity treatment.

Clinical Results and Expected Effects

Hanmi Pharmaceutical announced interim analysis results from a Phase 3 clinical trial in Korea involving 448 adult obese patients, showing an average weight reduction of 9.75% in the efpeglenatide group. The maximum individual weight reduction reached 30.14%. Notably, female patients with a Body Mass Index (BMI) below 30 kg/㎡ observed an average weight loss of 12.20%. These findings demonstrate that EPPE can be expected to yield substantial results in obesity treatment.

Hanmi Pharmaceutical's Vision for the Future

In December of last year, Hanmi Pharmaceutical applied for marketing approval for efpeglenatide auto-injector, and it has been designated as a Global Innovative Product on Fast Track (GIFT) by the Ministry of Food and Drug Safety. The company aims for approval and launch in the second half of this year. A representative from Hanmi Pharmaceutical stated their ambition: "Through EPPE, we aim to establish ourselves as Korea's leading brand for obesity and metabolic disease treatments."

Conclusion

The emergence of the obesity treatment EPPE serves as a new spark of hope for addressing the challenges of obesity. We anticipate that EPPE will bring about positive changes for many individuals suffering from obesity. We will be closely monitoring its progress, hoping it becomes a guiding light towards healthier lives.